Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 1
1972 1
1980 1
1985 2
1987 1
1989 2
1991 1
1992 3
1993 1
1994 3
1995 2
1996 1
1997 3
1998 2
2000 1
2001 1
2003 2
2004 1
2005 1
2006 1
2007 4
2008 1
2009 1
2010 6
2011 13
2012 5
2013 5
2014 3
2015 4
2016 9
2017 7
2018 7
2019 12
2020 12
2021 13
2022 5
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Congenital nevi.
Schleicher SM, Lim SJ. Schleicher SM, et al. Int J Dermatol. 1995 Dec;34(12):825-9. doi: 10.1111/j.1365-4362.1995.tb04414.x. Int J Dermatol. 1995. PMID: 8647657 Review. No abstract available.
Helping Patients With Cancer Navigate Narrow Networks.
Schleicher SM, Aviki EM, Feeley TW. Schleicher SM, et al. J Clin Oncol. 2017 Sep 20;35(27):3095-3096. doi: 10.1200/JCO.2017.74.5158. Epub 2017 Aug 10. J Clin Oncol. 2017. PMID: 28796586 No abstract available.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Coumarin necrosis.
Schleicher SM, Fricker MP. Schleicher SM, et al. Arch Dermatol. 1980 Apr;116(4):444-5. Arch Dermatol. 1980. PMID: 7369776
Innovation in Cancer Care Delivery in the Era of COVID-19.
Mullangi S, Schleicher SM, Aviki EM. Mullangi S, et al. Among authors: schleicher sm. JCO Oncol Pract. 2020 Nov;16(11):718-719. doi: 10.1200/OP.20.00336. Epub 2020 Jun 17. JCO Oncol Pract. 2020. PMID: 32552318 No abstract available.
TH1 cytokines induce senescence in AML.
Hashimoto H, Güngör D, Krickeberg N, Schmitt J, Doll L, Schmidt M, Schleicher S, Criado-Moronati E, Schilbach K. Hashimoto H, et al. Among authors: schleicher s. Leuk Res. 2022 Jun;117:106842. doi: 10.1016/j.leukres.2022.106842. Epub 2022 Apr 26. Leuk Res. 2022. PMID: 35490594 Free article.
136 results